Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinomaRodabe N. Amaria, Amir A. Jazaeri, Mara B. Antonoff et al.|Journal for ImmunoTherapy of Cancer|2024Cited by 54
Phase Ib study of AVB-S6-500 (axl inhibition) in combination with durvalumab (MEDI4736) in patients with platinum-resistant, recurrent epithelial ovarian cancer (NCT04019288) (320)Emily Hinchcliff, Amir A. Jazaeri, Elisabeth Gardiner et al.|Gynecologic Oncology|2022Cited by 1
A phase I study of tremelimumab, durvalumab, and hypofractionated radiotherapy for metastatic gynecologic cancers (040)Lilie L. Lin, Kevin Albuquerque, Diana L. Urbauer et al.|Gynecologic Oncology|2023Cited by 1